Jane Street’s Avadel Pharmaceuticals AVDL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-500,561
Closed -$10.8M 11544
2025
Q4
$10.8M Sell
500,561
-59,015
-11% -$1.15M ﹤0.01% 2240
2025
Q3
$8.54M Buy
559,576
+475,057
+562% +$6.18M ﹤0.01% 2621
2025
Q2
$748K Buy
+84,519
New +$743K ﹤0.01% 6163
2025
Q1
Sell
-100,118
Closed -$1.05M 9397
2024
Q4
$1.05M Buy
100,118
+1,561
+2% +$19K ﹤0.01% 5287
2024
Q3
$1.29M Buy
98,557
+30,039
+44% +$458K ﹤0.01% 5357
2024
Q2
$963K Buy
68,518
+11,913
+21% +$194K ﹤0.01% 5846
2024
Q1
$956K Sell
56,605
-53,300
-48% -$794K ﹤0.01% 5504
2023
Q4
$1.55M Buy
109,905
+88,225
+407% +$1.04M ﹤0.01% 4771
2023
Q3
$223K Sell
21,680
-236,370
-92% -$3.17M ﹤0.01% 7479
2023
Q2
$4.25M Buy
258,050
+232,151
+896% +$3.02M ﹤0.01% 2968
2023
Q1
$237K Sell
25,899
-49,000
-65% -$403K ﹤0.01% 7569
2022
Q4
$536K Buy
+74,899
New +$525K ﹤0.01% 6007
2022
Q3
Sell
-33,220
Closed -$81K 9665
2022
Q2
$81K Buy
33,220
+4,816
+17% +$19.8K ﹤0.01% 8750
2022
Q1
$194K Sell
28,404
-52,265
-65% -$359K ﹤0.01% 9050
2021
Q4
$652K Buy
+80,669
New +$737K ﹤0.01% 6766
2021
Q3
Sell
-17,397
Closed -$137K 9897
2021
Q2
$117K Sell
17,397
-61,808
-78% -$491K ﹤0.01% 9194
2021
Q1
$716K Buy
79,205
+61,660
+351% +$499K ﹤0.01% 6126
2020
Q4
$117K Buy
+17,545
New +$110K ﹤0.01% 7159
2019
Q4
Sell
-13,819
Closed -$57K 5030
2019
Q3
$57K Buy
+13,819
New +$34.6K ﹤0.01% 4863
2014
Q3
Sell
-18,523
Closed -$278K 2521
2014
Q2
$278K Buy
+18,523
New +$223K ﹤0.01% 1902

Other funds holding AVDL

Jane Street's AVDL Position: Q1 2026 in Review

Jane Street sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 500,561 shares — an estimated $10.8M sold.

Jane Street first reported a position in AVDL in Q2 2014 and held it in 20 quarters. The position peaked at $10.8M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Jane Street reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 500,561 Avadel Pharmaceuticals shares in Q1 2026, an estimated $10.8M.
  • Jane Street first reported a position in Avadel Pharmaceuticals in Q2 2014 and held it in 20 quarters.
  • Jane Street's Avadel Pharmaceuticals position peaked at $10.8M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.